Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738582 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
A Phase 2 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00738582: Completed Phase 2 study, sponsored by Morphotek.
NCT00738582 is a Phase 2 study that has completed, run by Morphotek. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00738582, a Phase 2 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
Primary Outcome
Number of participants with PFS responders and non-responders at Month 6 was reported. PFS was defined as the time from the date of the first dose of amatuximab to the date of disease progression or death due to any cause, as determined by independent radiologist based on the modified Response Evaluation Criteria in Solid Tumors (RECIST) utilizing the total tumor measurement (performed by computerized tomography (CT)/magnetic resonance imaging (MRI)) which includes the pleural unidimensional mea
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG MORAb-009 (Amatuximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-12-31 |
| Est. Completion | 2014-01-10 |
| Phase | Phase 2 |
What the finished NCT00738582 record still lists
NCT00738582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00738582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00738582 about?
NCT00738582 is a clinical study titled "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma". This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
What is the current status of trial NCT00738582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2008-12-31. Estimated completion is 2014-01-10.
What interventions are being tested in trial NCT00738582?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), MORAb-009 (Amatuximab) (DRUG).
Who is sponsoring clinical trial NCT00738582?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00738582's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI